FDA clears St. Jude cardiac mapping system
St. Jude Medical has announced the FDA clearance and U.S. launch of its EnSite Velocity cardiac mapping system, designed to help physicians diagnose and guide therapy to treat abnormal heart rhythms.
With new hardware and software, the system includes two new capabilities: the OneMap tool and RealReview function, the St. Paul, Minn.-based company said.
The OneMap tool enables physicians to create a cardiac model and electrical map using multiple catheters and electrodes.
The RealReview function provides side-by-side views of the live procedure and previously recorded portions of the procedure. This feature gives physicians a comparison of events and results at different times throughout the procedure, without losing the capability to visualize and navigate catheters.
According to St. Jude, the EnSite Velocity System is an open platform, which means that it is compatible with most diagnostic and ablation catheters, recording systems and energy sources used for ablation procedures.
With new hardware and software, the system includes two new capabilities: the OneMap tool and RealReview function, the St. Paul, Minn.-based company said.
The OneMap tool enables physicians to create a cardiac model and electrical map using multiple catheters and electrodes.
The RealReview function provides side-by-side views of the live procedure and previously recorded portions of the procedure. This feature gives physicians a comparison of events and results at different times throughout the procedure, without losing the capability to visualize and navigate catheters.
According to St. Jude, the EnSite Velocity System is an open platform, which means that it is compatible with most diagnostic and ablation catheters, recording systems and energy sources used for ablation procedures.